2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Aldose Reductase

Aldose Reductase

Aldose Reductase

Related Products

PDF 0.43 MB

Aldose reductase is a small, cytosolic, monomeric enzyme which belongs to the aldo-keto reductase superfamily. Aldose reductase catalyzes the reduced form of nicotinamide adenine dinucleotide phosphate (NADPH)-dependent reduction of a wide variety of aromatic and aliphatic carbonyl compounds. It is implicated in the development of diabetic and galactosemic complications involving the lens, retina, nerves, and kidney.

Aldose reductase is both the key enzyme of the polyol pathway, whose activation under hyperglycemic conditions leads to the development of chronic diabetic complications, and the crucial promoter of inflammatory and cytotoxic conditions, even under a normoglycemic status. Aldose reductase represents an excellent drug target and a huge effort is being done to disclose novel compounds able to inhibit it.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-147977
    ALR1/2-IN-1
    		Inhibitor
    ALR1/2-IN-1 (Compound 6e) is an aldehyde reductase (ALR1) and aldose reductase (ALR2) inhibitor with IC50 values of 3.26 μM and 3.06 μM against ALR1 and ALR2, respectively. ALR1/2-IN-1 shows anticancer activity.
    ALR1/2-IN-1
  • HY-N9335
    Myrciacetin
    		Inhibitor
    Myrciacetin is a flavonoid from Rhododendron dauricum. Myrciacetin is against rat lens aldose reductase with an IC50 of 13 μM.
    Myrciacetin
  • HY-N3716
    Dehydroglyasperin D
    		Inhibitor
    Dehydroglyasperin D inhibits rat and human Aldose Reductase (AR) (IC50: 62.4 μM and 176.2 μM respectively). Dehydroglyasperin D has anti-obesity, antioxidant effects. Dehydroglyasperin D shows anti-inflammatory activity by inhibiting COX-2 expression and the MLK3 signaling pathway. Dehydroglyasperin D also inhibits melanin synthesis. Dehydroglyasperin D is a prenylated flavonoid that can be isolated from Glycyrrhiza uralensi.
    Dehydroglyasperin D
  • HY-146661
    Aldose reductase-IN-4
    		Inhibitor
    Aldose reductase-IN-4 (compund IIc) is an aldose reductase inhibitor with IC50s of 11.70 μM and 0.98 μM for aldehyde reductase 1 (ALR1) and ALR2, respectively.
    Aldose reductase-IN-4
  • HY-155502
    AKR1C3-IN-10
    		Inhibitor
    AKR1C3-IN-10 (compound 5r) is a selective AKR1C3 inhibitor (IC50=51 nM). AKR1C3-IN-10 shows good activity in a prostate cancer xenograft model.
    AKR1C3-IN-10
  • HY-115940
    Aldose reductase-IN-2
    		Inhibitor
    Aldose reductase-IN-2 (Compound 5f) is a potent inhibitor of aldose reductase (AR). Aldose reductase-IN-2 has antioxidation capacity. Aldose reductase-IN-2 is a promising anti-diabetic complications agent.
    Aldose reductase-IN-2
  • HY-151946
    ALR2-IN-2
    		Inhibitor
    ALR2-IN-2 is a potent inhibitor of aldose reductase (ALR2), with IC50s of 27 nM and 228 nM for rat ALR2 and ALR1, respectively. ALR2-IN-2 can be used for the research of diabetic complications.
    ALR2-IN-2
  • HY-115977
    Aldose reductase-IN-3
    		Inhibitor
    Aldose reductase-IN-3 (Compound 5) is a potent and moderately selective inhibitor of aldose reductase (AR) with an IC50 of 3.99 μM. Aldose reductase has recently emerged as a molecular target that is involved in various inflammatory diseases, including sepsis. Aldose reductase-IN-3 has the potential for the research of sepsis.
    Aldose reductase-IN-3
  • HY-N6883
    6-Methoxytricin
    		Inhibitor
    6-Methoxytricin (Compound 6) is an flavonoid isolated from Artemisia iwayomogi. 6-Methoxytricin (Compound 6) is an inhibitor on aldose reductase (AR) and advanced glycation endproduct (AGE) formation activities with IC50 values of 30.29 μM and 134.88 μM, respectively. 6-Methoxytricin (Compound 6) has potential as an anti-diabetic complications agent.
    6-Methoxytricin
  • HY-N2494
    Hydroxyevodiamine
    		Inhibitor
    Hydroxyevodiamine (Rhetsinine) inhibits aldose reductase with an IC50 value of 24.1 μM.
    Hydroxyevodiamine
  • HY-D0064
    6,7-Dihydroxy-4-coumarinylacetic acid
    		Inhibitor
    6,7-Dihydroxy-4-coumarinylacetic acid is a potent and selective inhibitor of ALR2. 6,7-Dihydroxy-4-coumarinylacetic acid inhibits ALR2, SDH andALR1 with IC50s of 9.6, 288 and 66.3 μM, respectively. 6,7-Dihydroxy-4-coumarinylacetic acid clearly suppresses galactitol accumulation.
    6,7-Dihydroxy-4-coumarinylacetic acid
  • HY-122917
    Danshenol A
    		Inhibitor
    Danshenol A, an abietane-type diterpenoid, is an aldose reductase (AR) inhibitor with an IC50 of 0.1 μM. Danshenol A can protect endothelial cells from oxidative stress by directly scavenging ROS. Danshenol A has anti-inflammatory and antitumor properties. Danshenol A can be used for atherosclerosis research.
    Danshenol A
  • HY-147875
    Aldose reductase-IN-6
    		Inhibitor
    Aldose reductase-IN-6 (Compound 3) is a competitive aldose reductase (AR) inhibitor with an IC50 of 3.164 μM and a Ki of 0.018 μM. Aldose reductase-IN-6 exhibits no cytotoxicity against healthy cells.
    Aldose reductase-IN-6
  • HY-N12472
    Floramanoside C
    		Inhibitor
    Floramanoside C shows 2,2-diphenyl-1-picrylhydrazyl scavenging and aldose reductase inhibitory activities.
    Floramanoside C
  • HY-B1202A
    Alrestatin sodium
    		Inhibitor
    Alrestatin sodium is an inhibitor of aldose reductase, an enzyme involved in the pathogenesis of complications of diabetes mellitus, including diabetic neuropathy.
    Alrestatin sodium
  • HY-118819
    5-Bromo-3-phenyl salicylic acid
    		Inhibitor
    5-Bromo-3-phenyl salicylic acid is a selective inhibitor for human 20α-hydroxysteroid dehydrogenase (AKR1C1) with Ki of 140 nM.
    5-Bromo-3-phenyl salicylic acid
Cat. No. Product Name / Synonyms Application Reactivity